[{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Pari","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Liposomal Cyclosporine A","moa":"Calcineurin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Pari","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Pari"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Zambon Group SpA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Zambon Group SpA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Zambon Group SpA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Zambon Group SpA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Luye Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Rivastigmine","moa":"Cholinesterases; ACHE & BCHE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Zambon Group SpA \/ Zambon Group SpA","highestDevelopmentStatusID":"15","companyTruncated":"Zambon Group SpA \/ Zambon Group SpA"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Cross Research S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zambon Switzerland \/ Cross Research S.A.","highestDevelopmentStatusID":"6","companyTruncated":"Zambon Switzerland \/ Cross Research S.A."},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Voriconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Carbidopa","moa":"||DOPA decarboxylase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Zambon Group SpA \/ Zambon Group SpA","highestDevelopmentStatusID":"15","companyTruncated":"Zambon Group SpA \/ Zambon Group SpA"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zambon Group SpA \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zambon Group SpA \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthetase; Cystine\/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthetase; Cystine\/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthetase; Cystine\/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Zambon Switzerland","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthetase; Cystine\/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Effervescent","sponsorNew":"Zambon Switzerland \/ Zambon Switzerland","highestDevelopmentStatusID":"6","companyTruncated":"Zambon Switzerland \/ Zambon Switzerland"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Zambon Switzerland","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Rosuvastatin Calcium","moa":"HMG-CoA reductase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zambon Switzerland \/ Zambon Switzerland","highestDevelopmentStatusID":"6","companyTruncated":"Zambon Switzerland \/ Zambon Switzerland"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Safinamide Methanesulfonate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Safinamide Methanesulfonate","moa":"Monoamine oxidase B","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Newron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Safinamide Methanesulfonate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zambon Switzerland \/ Newron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Zambon Switzerland \/ Newron Pharmaceuticals"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Newron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Safinamide Methanesulfonate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zambon Group SpA \/ Zambon Group SpA","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Zambon Group SpA"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Zambon Switzerland","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Riluzole","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Film, Dispersible","sponsorNew":"Zambon Switzerland \/ Zambon Switzerland","highestDevelopmentStatusID":"6","companyTruncated":"Zambon Switzerland \/ Zambon Switzerland"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Ab-Biotics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"KABP022","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zambon Group SpA \/ Zambon Group SpA","highestDevelopmentStatusID":"1","companyTruncated":"Zambon Group SpA \/ Zambon Group SpA"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Safinamide Methane Sulfonate","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase IV","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Safinamide Methane Sulfonate","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Safinamide Methane Sulfonate","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"FLUIDDA","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Z7200","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Switzerland \/ FLUIDDA","highestDevelopmentStatusID":"8","companyTruncated":"Zambon Switzerland \/ FLUIDDA"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Z7200","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Z7200","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zambon Switzerland \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Zambon Group SpA
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
